A PHASE I/IB SINGLE ARM STUDY OF TWO FRACTION SBRT WITH DOMINANT LESION SIB FOR THE TREATMENT OF LOCALIZED PROSTATE CANCER

Brief description of study

Phase I/IB, single arm trial of Two-Fraction SBRT with an MRI directed, dominant intraprostatic lesion, simultaneous integrated boost based on genomic classification in the treatment of localized prostate cancer. Primary endpoint will be physician-reported grade 2 or higher CTCAE toxicity. Secondary endpoints are: EPIC quality of life, PSA Nadir, and Phoenix Definition Biochemical failures as well as Disease Free Survival, Overall Survival, and MFS.


Clinical Study Identifier: s22-01306
ClinicalTrials.gov Identifier: NCT05864196
Principal Investigator: Jonathan W Lischalk.
Other Investigators: Maya Dimitrova, Hank Ng, Victor Ricardo Adorno Febles, Todd J Carpenter, Anthony Corcoran, Mary K O'Keeffe, Moses M Tam, Samir Taneja, Angela Tong, Jonathan Haas, Aaron Edward Katz, William C Huang, Michael J. Zelefsky, David Jaihun Byun, David R. Wise.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.